We are live on
!
Find out more
EC
Elmind Capital Portfolio holdings
AUM
$352M
This Fund
S&P 500
This Quarter
Est. Return
+12.77%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$352M
AUM Growth
+$13.4M
(+3.9%)
Cap. Flow
-$7.13M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
68.76%
Holding
36
New
2
Increased
7
Reduced
6
Closed
2
Top Buys
| 1 |
CytomX Therapeutics
CTMX
|
+$19.5M |
| 2 |
DBVT
DBV Technologies
DBVT
|
+$5.54M |
| 3 |
KALV
KalVista Pharmaceuticals
KALV
|
+$3.55M |
| 4 |
ALMS
Alumis Inc
ALMS
|
+$3.25M |
| 5 |
Cullinan Oncology
CGEM
|
+$2.83M |
Top Sells
| 1 |
CG Oncology
CGON
|
+$11.4M |
| 2 |
DVAX
Dynavax Technologies
DVAX
|
+$10.5M |
| 3 |
Viridian Therapeutics
VRDN
|
+$9.61M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$8.93M |
| 5 |
Wave Life Sciences
WVE
|
+$3.52M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cogent Biosciences
COGT
$6.4B
| $45.1M | 12.79% |
1,170,740
| – | – |
|
2
Syndax Pharmaceuticals
SNDX
$2.03B
| $43.3M | 12.3% |
1,855,000
| – | – |
|
3
Celldex Therapeutics
CLDX
$3.02B
| $27.4M | 7.79% |
865,000
| – | – |
|
|
4
CytomX Therapeutics
CTMX
$806M
| $21.4M | 6.07% |
4,550,000
+3,850,000
| +550% | +$19.5M |
|
|
KALV
5
DELISTED
KalVista Pharmaceuticals
KALV
| $20.6M | 5.84% |
1,021,300
+220,000
| +27% | +$3.55M |
|
|
6
CG Oncology
CGON
$6.39B
| $19.7M | 5.61% |
291,800
-200,700
| -41% | -$11.4M |
|
7
Vera Therapeutics
VERA
$2.98B
| $19.4M | 5.51% |
482,500
| – | – |
|
8
Vaxcyte
PCVX
$8.23B
| $18.4M | 5.22% |
316,500
+25,000
| +9% | +$1.36M |
|
9
Pharvaris
PHVS
$2.45B
| $13.4M | 3.82% |
475,750
| – | – |
|
10
Tyra Biosciences
TYRA
$1.94B
| $13.4M | 3.81% |
350,000
| – | – |
|
11
Beam Therapeutics
BEAM
$3.19B
| $11.4M | 3.22% |
476,338
| – | – |
|
|
12
Viridian Therapeutics
VRDN
$2.1B
| $10.5M | 2.97% |
534,931
-323,700
| -38% | -$9.61M |
|
|
13
BioCryst Pharmaceuticals
BCRX
$2.52B
| $9.52M | 2.7% |
1,000,000
-1,150,000
| -53% | -$8.93M |
|
14
United Therapeutics
UTHR
$22.7B
| $8.89M | 2.53% |
15,000
+4,000
| +36% | +$1.99M |
|
|
15
Cullinan Oncology
CGEM
$1.1B
| $7.53M | 2.14% |
530,000
+220,000
| +71% | +$2.83M |
|
16
Nurix Therapeutics
NRIX
$2.36B
| $7.13M | 2.02% |
460,000
| – | – |
|
|
MBX
17
MBX Biosciences
MBX
$2.86B
| $6.3M | 1.79% |
211,000
| – | – |
|
18
Krystal Biotech
KRYS
$10.7B
| $5.68M | 1.61% |
22,000
| – | – |
|
|
DBVT
19
DBV Technologies
DBVT
$946M
| $5.54M | 1.57% |
+265,000
| New | +$5.54M |
|
20
Relay Therapeutics
RLAY
$4.08B
| $5.34M | 1.52% |
536,946
| – | – |
|
21
Travere Therapeutics
TVTX
$5.23B
| $5.28M | 1.5% |
177,600
+67,600
| +61% | +$2.02M |
|
22
Protagonist Therapeutics
PTGX
$8.35B
| $4.01M | 1.14% |
38,000
| – | – |
|
23
UroGen Pharma
URGN
$1.92B
| $3.96M | 1.12% |
220,000
+120,000
| +120% | +$2.41M |
|
|
ALMS
24
Alumis Inc
ALMS
$3.58B
| $2.86M | 0.81% |
+130,000
| New | +$3.25M |
|
25
BioMarin Pharmaceuticals
BMRN
$11.4B
| $2.66M | 0.75% |
47,000
-35,000
| -43% | -$2.04M |
|
Similar funds
PIC
MCMU
SC
FWM
BMWM
ACA
BFS
BL